GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CEO Katherine Stueland sold 10,559 shares of the business's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $96.71, for a total value of $1,021,160.89. Following the sale, the chief executive officer now owns 14,865 shares of the company's stock, valued at $1,437,594.15. The trade was a 41.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Katherine Stueland also recently made the following trade(s):
- On Thursday, March 13th, Katherine Stueland sold 1,078 shares of GeneDx stock. The shares were sold at an average price of $89.44, for a total transaction of $96,416.32.
- On Monday, March 10th, Katherine Stueland sold 2,731 shares of GeneDx stock. The shares were sold at an average price of $94.73, for a total transaction of $258,707.63.
- On Wednesday, January 29th, Katherine Stueland sold 1,657 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36.
- On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The shares were sold at an average price of $94.48, for a total value of $4,858,161.60.
- On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total value of $1,407,709.08.
GeneDx Trading Up 7.9 %
Shares of GeneDx stock traded up $7.68 on Friday, reaching $104.39. The company had a trading volume of 704,762 shares, compared to its average volume of 617,273. The firm's 50 day moving average price is $84.59 and its two-hundred day moving average price is $71.15. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. GeneDx Holdings Corp. has a 52-week low of $8.10 and a 52-week high of $115.60. The firm has a market cap of $2.93 billion, a PE ratio of -53.26 and a beta of 1.91.
GeneDx (NASDAQ:WGS - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.66. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The company had revenue of $95.64 million for the quarter, compared to analysts' expectations of $82.24 million. Sell-side analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on WGS shares. TD Cowen raised their target price on GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a research note on Tuesday, January 7th. The Goldman Sachs Group lifted their price target on shares of GeneDx from $70.00 to $80.00 and gave the company a "neutral" rating in a research report on Wednesday, February 19th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat, GeneDx currently has an average rating of "Moderate Buy" and an average price target of $72.33.
View Our Latest Report on WGS
Hedge Funds Weigh In On GeneDx
Hedge funds and other institutional investors have recently bought and sold shares of the company. California State Teachers Retirement System boosted its position in GeneDx by 13.3% in the 4th quarter. California State Teachers Retirement System now owns 11,384 shares of the company's stock valued at $875,000 after buying an additional 1,335 shares during the period. Polar Asset Management Partners Inc. purchased a new stake in shares of GeneDx during the 4th quarter worth $1,007,000. Palisades Investment Partners LLC acquired a new position in shares of GeneDx during the fourth quarter worth $6,425,000. Castleark Management LLC purchased a new position in GeneDx in the fourth quarter valued at $4,743,000. Finally, PharVision Advisers LLC acquired a new stake in GeneDx in the fourth quarter valued at $301,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.
About GeneDx
(
Get Free Report)
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Read More
Before you consider GeneDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GeneDx wasn't on the list.
While GeneDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
